Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | HTR1B | P28222 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585616 | 0.96 | KDM4E (0.47) | KDM4EHTR1BSLC6A2HTR7SMN1; SMN2 | |
| SCHEMBL238407 | 0.91 | HTR7 (0.53) | KDM4EHTR1BSLC6A2HTR7SMN1; SMN2 | |
| SCHEMBL5585671 | 0.81 | SLC6A2 (0.46) | KDM4ESLC6A2HTR7SMN1; SMN2ALDH1A1 | |
| SCHEMBL5585305 | 0.80 | KDM4E (0.46) | KDM4EHTR1BHTR7SMN1; SMN2ALDH1A1 | |
| SCHEMBL5585853 | 0.79 | CHRNB2 (0.49) | SLC6A2HTR7 | |
| SCHEMBL236730 | 0.79 | SLC6A2 (0.47) | KDM4ESLC6A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL5585335 | 0.77 | SLC6A2 (0.42) | KDM4ESLC6A2HTR7SMN1; SMN2ALDH1A1 | |
| SCHEMBL4318642 | 0.77 | CHRNB4 (0.48) | SLC6A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL5585621 | 0.77 | SLC6A2 (0.62) | KDM4EHTR1BSLC6A2ALDH1A1HRH1 | |
| SCHEMBL4954593 | 0.75 | PDE5A (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226925-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2007-06-05 | — | — | US | disclosed |
| EP-1513831-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | disclosed |
| WO-2004000830-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029888-A1 | Novel compounds, their use and preparation | TPH1, TPH2, HTR1A | KDM4E 3125/4885HTR1B 4/4885SLC6A2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.